Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Breast Carcinoma|Refractory Breast Carcinoma
Interventions: DRUG: Cyclophosphamide|BIOLOGICAL: Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM|BIOLOGICAL: Pembrolizumab|BIOLOGICAL: Recombinant Interferon Alpha 2b-like Protein|OTHER: Questionnaire Administration|OTHER: Quality of Life Assessment
Sponsor: Thomas Jefferson University